Wednesday, February 24, 2016
Stemedica International Receives Approval from Emory University to Initiate Alzheimer’s Disease Study with Adult Allogeneic Stem Cells
Lausanne, Switzerland — February 24, 2016 — Stemedica International, SA, a leader in the development of innovative stem cell-based treatments for Alzheimer’s Disease announced today that it has received IRB approval from Emory University in Atlanta, Georgia to initiate a clinical study entitled, “A Phase IIa Multicenter, Randomized, Single-blind, Placebo-controlled, Crossover Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Human Mesenchymal Stem Cells in Subjects with Mild to Moderate Dementia Due to Alzheimer’s Disease.”This study will enroll approximately 40 subjects diagnosed with mild to moderate dementia at least 3 months prior to enrollment, based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) Alzheimer’s criteria.
“We are very excited to take this next step in our clinical plan to develop a treatment for this devastating disease”, says Nikolai Tankovich, M.D., Ph.D., President and Chief Medical Officer of Stemedica Cell Technologies and Executive Chairman for Stemedica International “We will begin treating patients later this year at multiple clinical trial sites.”
source url initial use of viagra cheap viagra birmingham uchicago essays source url https://www.dimensionsdance.org/pack/2264-viagra-auf-rechnung.html where to buy viagra in perth wa follow site viagra soft tabs kaufen cheap generic viagra+free shipping lincoln paper help my essay see url buy womens viagra uk thesis paper on leadership https://www.xpcc.com/geometry-help/ source http://www.jfshea.com/15117-what-foods-affect-cialis/ click here enter site follow site how to write college essay med tabs is there a recall on ventolin hfa inhalers viagra dangers see short essay example shipping viagra canada https://www.dimensionsdance.org/pack/11710-uaw-union-gets-viagra.html next day delivery generic viagra About Stemedica International S.A.
Stemedica International S.A. is a biotechnology company that develops therapeutic applications for the treatment and prevention of Alzheimer’s disease and vascular dementia. The company is a subsidiary of Stemedica Cell Technologies, Inc., a global biotechnology company that manufactures adult allogeneic stem cells. Stemedica International has the worldwide rights to manufacture and distribute the parent company’s allogeneic, ischemia-tolerant mesenchymal stem cell (itMSC) and ischemia-tolerant neural stem cell (itNSC) lines and stem cell factors for Alzheimer’s disease and vascular dementia indications. The company also has Swissmedic licenses to import, export and distribute Stemedica Cell Technologies’ cell lines worldwide for human use in approved clinical trials. Manufactured in compliance with cGMP standards, the stem cell lines have a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. For more information, visit www.stemedica-intl.com.
Forward Looking Statements
This press release may contain forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance and you are cautioned not to place undue reliance on these forward-looking statements. These statements reflect the views of Stemedica as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
Media and Business Contact
Stemedica International S.A.
+41 (0)78 794 7232